News from the Bench
Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.
CST Antibody Performance Guarantee
To Purchase # 12998S
Find answers on our FAQs page.
PTM information and tools available.
Western blot analysis of extracts from NCI-H526 cells, serum-starved overnight and untreated (-) or pretreated with Vatalanib (1000 nM, 2 hr; +) prior to treatment with Human Stem Cell Factor (hSCF) #8925 (100 ng/ml, 5 min; +), using Phospho-c-Kit (Tyr703) (D12E12) Rabbit mAb #3073 (upper) or c-Kit (D13A2) XP® Rabbit mAb #3074 (lower).Learn more about how we get our images
Western blot analysis of extracts from HUVE cells, serum-starved overnight and untreated (-) or pretreated with Vatalanib (1000 nM, 2 hr; +) prior to treatment with Human Vascular Endothelial Growth Factor-165 (hVEGF165) #8065 (50 ng/ml, 5 min; +), using Phospho-VEGF Receptor 2 (Tyr1175) (19A10) Rabbit mAb #2478 (upper) or VEGF Receptor 2 (55B11) Rabbit mAb #2479 (lower).Learn more about how we get our images
Gallery: Vatalanib #12998
Vatalanib is supplied as a lyophilized powder. For a 10 mM stock, reconstitute the 5 mg in 1.19 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used as a pretreatment at 0.5-50 μM for 0.5-2 hr prior to treating with a stimulator. It can also be used alone, with varying treatment times lasting up to 72 hr.Storage: Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Vatalanib is a multi-targeted tyrosine kinase inhibitor. Researchers performing in vitro kinase assays show that vatalanib inhibits VEGFR-1, -2, and -3 with IC50 values of approximately 77 nM, 37 nM, and 640 nM, respectively. Vatalanib also inhibited PDGFR and c-kit at sub micromolar concentrations, but had no activity against several other kinases, including c-Met, EGFR, c-Src, and v-Abl up to 10 μM (1). Vatalanib inhibits VEGF-induced autophosphorylation in HUVE and VEGFR-2 transfected CHO cells with an IC50 of 17 nM and 34 nM, respectively, and effectively blocks VEGF-stimulated HUVE cell proliferation (1). Research studies have demonstrated that vatalanib inhibits proliferation of multiple myeloma (MM) cells in a dose-dependant manner and blocks VEGF-induced ERK phosphorylation and cell migration in MM.1S cells (2). Dose-dependent apoptosis in chronic lymphocytic leukemia (CLL) cells by vatalanib and pazopanib has been observed (3).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc. XP® is a trademark of Cell Signaling Technology, Inc.